Understand the source comparison
Peptide Classification: Opioid-Modulating vs Receptor-Independent
Not all peptides interact with opioid receptors. Classifying compounds by receptor mechanism determines whether timing relative to LDN matters at all. Opioid-modulating peptides include BPC-157, delta sleep-inducing peptide (DSIP), beta-endorphin analogs, and
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Not all peptides interact with opioid receptors. Classifying compounds by receptor mechanism determines whether timing relative to LDN matters at all. Opioid-modulating peptides include BPC-157, delta sleep-inducing peptide (DSIP), beta-endorphin analogs, and certain thymic peptides like Thymalin. These rely on endogenous opioid signaling for immune modulation, pain reduction, or tissue repair. Receptor-independent peptides include growth hormone secretagogues (GHRP-2, GHRP-6, CJC-1295, MK-677), GLP-1 agonists, metabolic enhancers like Tesofensine, and nootropic peptides like P21 or Dihexa.
- The practical distinction: if a peptide's primary mechanism doesn't involve mu-opioid, delta-opioid, or kappa-opioid receptors, LDN timing is irrelevant. Growth hormone secretagogues work through ghrelin receptor agonism. No opioid interaction exists. You can dose GHRP-2 at 6 AM and LDN at 10 PM without losing efficacy. The same applies to metabolic compounds like Survodutide or Mazdutide, which act on GLP-1 and glucagon receptors with zero opioid pathway involvement.
- Opioid-modulating peptides require strategic spacing. BPC-157's tissue repair effects depend partly on enkephalin signaling. Blocking that pathway with LDN reduces efficacy. Thymalin's immunomodulatory activity involves beta-endorphin upregulation in thymic tissue, which LDN temporarily suppresses. The timing protocol for these compounds must account for 6-beta-naltrexol clearance, not just naltrexone clearance. That's the 11–13 hour window most protocols miss.